NICE Recommends Alexion’s Anticoagulant Ondexxya With Conditions

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Alexion’s Ondexxya (andexanet alfa) for National Health Service use for reversing the anticoagulant effects of apixaban or rivaroxaban in adults with potentially fatal gastrointestinal tract bleeding.

Apixaban and rivaroxaban are used to prevent and treat blood clots, such as in deep vein thrombosis and pulmonary embolism. While treatment with the drugs can help stop clots from forming, they can also lead to major bleeding events, NICE said.

The institute advised that Ondexxya could be used for gastrointestinal bleeding but said the available data do not support its use for intracranial hemorrhage or bleeding elsewhere in the body.